The cardiovascular phenotype: Impact on choice of glucose-lowering therapy

Journal of the Pakistan Medical Association

Volumn 66, Issue 4, 2016, Pages 480-482

  Kalra, Sanjay ^a   Gupta, Yashdeep ^b   Kishor, Kamal ^c  

^a BHARTI HOSPITAL   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^c Cygnus Hospital   (India)

Author keywords

Acarbose; Cardiovascular outcome trials; Cardiovascular Phenotype; Diabetes; Dyslipidaemia; Empagliflozin; Metformin; Obesity; Overweight

Indexed keywords

A; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; EMPAGLIFLOZIN; GLIBENCLAMIDE; GLICLAZIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; INSULIN GLARGINE; PIOGLITAZONE; ROSIGLITAZONE; SAXAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; METFORMIN;

ACUTE CORONARY SYNDROME; ARTERIAL WALL THICKNESS; ARTICLE; CARDIOVASCULAR DISEASE ASSESSMENT; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR PHENOTYPE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHECKLIST; DIASTOLIC BLOOD PRESSURE; DRUG CHOICE; DRUG SAFETY; DYSPNEA; FATIGUE; HEART RATE; LIPID BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PERIPHERAL VASCULAR SYSTEM; PHENOTYPE; PULSE RATE; TREATMENT PLANNING; WEIGHT GAIN; WEIGHT REDUCTION; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; COMPLICATION; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIA; HUMAN; PATHOPHYSIOLOGY;

ACARBOSE; BENZHYDRYL COMPOUNDS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; GLUCOSIDES; HEART RATE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; OBESITY; PHENOTYPE;

EID: 84961942939     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Kalra S, GuptaY.Theglucophenotype. J PakMedAssoc. 2016; 1:118-119
2. Kalra S, Gupta Y. Insulin initiation: Bringing objectivity to choice. Journal of Diabetes & Metabolic Disorders 2015; 14: 17.
3. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New Engl J Med 2015; epub ahead of print: DOI: 10.1056/NEJMoa1504720
4. Fisman EZ, Tenenbaum A. Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes. Cardiovascular diabetology 2015; 14: 129.
5. McElhinney DB, Krantz ID, Bason L, Piccoli DA, Emerick KM, Spinner NB, et al. Analysis of cardiovascular phenotype and genotype-phenotype correlation in individuals with a JAG1 mutation and/or Alagille syndrome. Circulation 2002; 106: 2567-2574.
6. Lindman BR, Dávila-Román VG, Mann DL, McNulty S, Semigran MJ, Lewis GD, et al. Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study. Journal of the American College of Cardiology 2014; 64: 541-549.
7. Robinson LE, Holt TA, Rees K, Randeva HS, O'Hare JP. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open, 2013; 3: e001986.
8. Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. Journal of the American Society of Hypertension 2014; 8: 262-275.
9. Negro R, Dazzi D, Hassan H, Pezzarossa A. Pioglitazone reduces blood pressure in non-dipping diabetic patients. Minerva Endocrinologica 2004; 29: 11-17.
10. Weng J, Soegondo S, Schnell O, Sheu WHH, Grzeszczak W, Watada H, et al. Efficacy of acarbose in different geographical regions of the world: analysis of a real-life database. Diabetes/metabolism research and reviews 2015; 31: 155-167.
11. Florez H, Reaven P, Bahn G, Moritz T, Warren S, Marks J, et al. Rosiglitazone Treatment and Cardiovascular Disease in the Veterans Affairs Diabetes Trial. Diabetes, Obesity andMetabolism2015; 17: 949-955.
12. Kalra S, Aamir A H, Raza A, Das A K, Azad Khan A K, Shrestha D, et al. Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement. Indian J Endocr Metab 2015;19:577-96
13. Kalra S, Kalra B, Unnikrishnan AG, Agrawal N, Kumar S. Optimizing weight control in diabetes: antidiabetic drug selection. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010; 3: 297-299.
14. Wu S, Hopper I, Skiba M, Krum H. Dipeptidyl Peptidase-4 Inhibitors and Cardiovascular Outcomes: Meta-Analysis of Randomized Clinical Trials with 55,141 Participants. Cardiovasc Therap 2014; 32, 147-158.
15. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOPNIDDM trial. JAMA 2003; 290: 486-494.